ASC30在美国进行两阶段的肥胖治疗试验。 Ascletis Pharma launches two Phase I trials for obesity treatment ASC30 in the U.S.

亚斯克莱蒂斯制药公司已在美国启动两项I期临床试验,用于其肥胖治疗,ASC30,一种小分子GLP-1R激动剂. Ascletis Pharma Inc. has launched two Phase I clinical trials in the U.S. for its obesity treatment, ASC30, a small molecule GLP-1R agonist. 试验将评估每月一次的皮下注射和每天一次的口服片剂. The trials will evaluate both a once-monthly subcutaneous injection and a once-daily oral tablet formulation. 这标志着阿斯克利蒂斯进入肥胖药物市场,目的是通过创新的提供方法解决体重管理问题。 This marks Ascletis' entry into the obesity drug market, aiming to address weight management through innovative delivery methods.